Chronic myeloid leukemia (CML) is a malignant hematopoietic stem cell disorder. It is characterized by the presence of the Philadelphia (Ph) chromosome, which contains the chimeric BCR-ABL fusion gene encoding a constitutively active tyrosine kinase. Targeted inhibition of BCR-ABL kinase protein by imatinib (Glivec), a tyrosine kinase inhibitor, induces complete cytogenetic response (CCR) in 70-90% of chronic-phase CML patients with minute side effects, 1 and is the drug of choice for all newly diagnosed CML patients.
Imatinib therapy is regarded lifelong, as rapid disease relapse has been reported in several case reports upon drug discontinuation. However, in a small proportion of patients with a very low level of minimal residual disease, imatinib discontinuation may be feasible. 2 The mechanisms behind this 'operational cure' are unknown, but can be related to anti-CML immunity, possibly induced by the preceding interferon (IFN) a therapy in these patients. However, imatinib may also have immunomodulatory properties, which can be important in the long-term control of CML. In patients relapsing after allogeneic stem cell transplantation, imatinib has an additive effect on donor lymphocyte infusions in inducing remissions, and it restores the dendritic cell function important in the recognition of tumor cells in vitro and in vivo.
The morphological and functional changes in bone marrow (BM) during imatinib therapy are not well characterized. The decrease in cellularity, the clearance of pathological megakaryocytes and a marked reduction of granulopoiesis are known rapid events in BM morphology after the start of therapy. In clinical laboratory practice, an excess of lymphocytes is often observed in BM aspirates during imatinib therapy. An increased incidence of lymphoid nodules has also been reported in BM biopsies. 3 The aim of this study was to assess the dynamic morphological changes in BM induced by imatinib treatment. We postulated that the increase in BM lymphocyte count may reflect immune activation and may be related to therapeutic response.
We analyzed BM aspirate samples from adult CML patients in chronic phase (n ¼ 37) during imatinib therapy at a single institution. Most patients (n ¼ 30) participated in prospective clinical studies, where imatinib was used as a first-line therapy (three patients with IFN a combination therapy). In addition, seven patients were treated with hydroxyurea and/or IFN before imatinib therapy. The patients used standard dose (400 mg) of imatinib, with dose increases to 600-800 mg in non-responding patients. All patients were in chronic phase and only samples during the imatinib therapy were analyzed. The study was conducted in accordance with the principles of the Helsinki declaration and was approved by the Helsinki University Central Hospital Ethics Committee.
Response to therapy was assessed at 12 months and was classified according to the guidelines of European LeukemiaNet into optimal, suboptimal and failure. 4 Only patients observed for at least 12 months were included in the analyses. Results of routine laboratory tests (blood cell counts, differential analysis of leukocytes and C-reactive protein) were obtained from the patients at the time when BM aspirate samples were taken.
The BM aspirate samples were taken every 3 months during imatinib therapy. Two representative preparations from each aspirate sample were stained with May-Grü nwald-Giemsa (MGG) staining. A total of 204 BM aspirate samples and two slides from each sample were analyzed blinded to therapeutic response. The slides were marked with random numbers and the patients' identity was unknown to the hematologist who evaluated the slides. Preparations considered to be of inferior quality (for example, insufficient amount of BM matrix tissue and cells) were excluded from analyses (n ¼ 11). The cellularity of the BM aspirates was evaluated and scored as normal, hypocellular or hypercellular. The percentage of lymphocytes was counted from four different fields, and the percentage of blasts and basophils were counted from two separate fields. In total, eight separate fields from each BM aspirate sample were counted for assessing BM lymphocytosis. The mean and median values for percentages of lymphocytes, blasts and basophils were counted from the raw values. The upper normal BM lymphocyte count was defined as 24% from the total number of nucleated cells. 5 Karyotyping of a total of 20 mitotic cells was performed using the standard G-banding method. In follow-up samples, G-banding was complemented with a high-resolution fluorescence in situ hybridization (metaphase FISH) as described. 6 The frequency of residual Ph þ cells was determined in most cases from 500 to 1000 metaphase cells. Molecular genetic analysis of BCR-ABL transcripts was performed with real-time quantitative PCR (RQ-PCR) using TaqMan chemistry. The mononuclear cell fraction of BM and peripheral blood (PB) samples was used for total RNA isolation. RT reaction conditions and RQ-PCR assays were performed according to the protocol of Europe Against Cancer Program with b-glucuronidase (GUS) as the reference gene. Commercial BCR-ABL and GUS plasmid standards (Ipsogen, Marseilles, France) were used for quantification of transcripts. The molecular response to treatment was determined as a log 10 reduction of BCR-ABL/GUS ratio in follow-up samples from the laboratory median of diagnostic BCR-ABL/GUS ratios.
Immunophenotyping was performed using antibodies against the following antigens: CD3, CD4, CD5, CD7 (eBioscience, San Diego, CA, USA), CD8, CD11c, CD14, CD16, CD19, CD20, CD25, CD34, CD38, CD16/56, CD45, CD56, CD57, CD117 (DAKO, Glostrup, Denmark), CD133 (Miltenyi Biotech, Bergisch Gladbach, Germany), CD206, TCR-a/b, TCR-g/d, kappa light (DAKO), lambda light chain (DAKO), with isotype controls. The antibodies were purchased from BD Biosciences (San Jose, CA, USA), if not otherwise mentioned. The analysis of dendritic cells was performed with the Miltenyi's DC kit, and regulatory T cells (Tregs) were characterized with FoxP3 (clone PCH101, eBioscience) and CD25 staining according to the manufacturer's instructions. The flow cytometric analysis was performed using FACS Calibur (BD Biosciences) and 1-5 Â 10 5 cells were analyzed depending on the cell type. The final analysis of the data was performed with WinList 6.0 (Verity Software House) or FACSdiva 4.1 (BD) software.
The statistical evaluation of the data was performed using SPSS software (version 14.0 for Windows, SPSS Inc.). Fisher's exact, Kruskal-Wallis and Spearman rank correlation (r) tests were used for comparison of the results. Results were considered statistically significant at Pp0.05.
In 37 CML patients enrolled into this study, the female/male ratio was 12:25 and the median age at the time of diagnosis was 51 years (range, 22-77 years). The therapy response to imatinib in 18 patients was regarded as optimal, in seven patients as suboptimal and in eight patients as failure. Failure patients were intentionally overrepresented in this study as compared to a population-based material to have sufficient power in statistical calculations. At the time of analysis, four patients were not classifiable in any of the above-mentioned groups owing to the short follow-up time (o12 months). The median follow-up time during imatinib therapy was 18 months. No statistically significant differences were found between the response groups and blood cell counts, spleen size or age at the time of diagnosis. Similarly, the median follow-up time and imatinib dose during therapy were comparable in the various groups. The number of low-, intermediate-and high-risk patients according to Sokal and Hasford classifications tended to be unevenly distributed in various response groups (Table 1) .
By the end of 6 months, the patients had normal or slightly decreased cellularity in the BM and no morphological signs of CML ( Figure 1 ). All patients, except one failure patient, achieved complete hematological response after 6 months of imatinib treatment. In a proportion of patients, an increased amount of lymphocytes was noted in BM follow-up samples during imatinib therapy. Morphologically, the lymphocytes were scattered in between other cell types and were not in tight clusters or foci (Figures 1b and c) . The lymphocytes varied in size and shape, and included immature forms.
We counted the mean percentage of lymphocytes of four separate fields from two slides (final lymphocyte count calculated as an average of eight fields). Mean lymphocyte values from two separate preparations correlated well (r ¼ 0.83, Pp0.001) and thus the within-sample variation between BM smear preparations was small. Before start of imatinib therapy, none of the patients had an increased amount of lymphocytes in the BM (median percentage of lymphocytes, 3%). After Letters to the Editor 3 months of imatinib therapy, the cellularity in the BM had decreased and was normal in 36/37 patients. The median BM lymphocyte counts during imatinib therapy were 17% at 3 months, 20% at 6 months and 14% at 12 months, but with a wide between-patient variation. The amount of lymphocytes in the BM aspirates did not correlate with the white blood cell or absolute lymphocyte count in the PB (r ¼ À0.22 and 0.13, respectively). We next assessed the relation of BM lymphocyte count to imatinib response. The median lymphocyte count was different in failure, suboptimal and optimal response groups at 3 months (10, 19 and 25%; Po0.05) and at 6 months (11, 11 and 26%; Po0.05). At 3 months of imatinib therapy, none of the failure patients (0/8) and only 29% of suboptimal patients (2/7) had an increased amount of lymphocytes (424%) in the BM. In the optimal response group, 56% of patients (10/18) had BM lymphocytosis (Figures 1 and 2) . Similarly, at 6 months after the start of imatinib therapy, 13% (failure), 29% (suboptimal) and 56% (optimal) of patients had an increased amount of lymphocytes in the BM aspirates. To exclude random variations in BM lymphocyte counts, we only rated patients who, after a 12 months follow-up time, had at least two BM follow-up samples with a lymphocyte count of 424%. With this categorization, 56, 29 and 0% of patients had BM lymphocytosis in optimal, suboptimal and imatinib failure response groups, respectively (P ¼ 0.005). No apparent differences between patients with (n ¼ 11) or without lymphocytosis (n ¼ 12) in the optimal and suboptimal groups could be found with respect to age, Hasford or Sokal risk groups, spleen size, blood counts, human leukocyte antigen subtype or lactate dehydrogenase values at diagnosis. With time, the median lymphocyte counts decreased in the optimal response group, but some patients still had regional increase of lymphocytes after 12 months of therapy (Figure 2) .
The amount of lymphocytes in BM correlated well with the cytogenetic results. At 3 months, 91% of patients who had increased amount of lymphocytes had a major cytogenetic response (MCR; p35% of Ph þ cells in the BM) and similarly 92% of patients without MCR had normal lymphocyte count (P ¼ 0.02). Similarly at 6 months, 92% of patients with increased amount of lymphocytes had MCR (P ¼ 0.02).
In patients with a poor response to imatinib therapy, dose escalation was made either to 600 or 800 mg/day. The amount of lymphocytes in the BM remained normal even with higher doses of imatinib, if no cytogenetic response was achieved. In a few patients, however, the dose increase was associated with BM lymphocytosis and also cytogenetic response was observed (Supplementary Figure 3) .
To elucidate the nature of BM lymphocytes, the flow cytometric analysis was performed from BM aspirates and PB samples, when available (n ¼ 19). Five samples from CML patients at diagnosis served as controls. In general, the lymphocyte proliferation observed in optimal responding patients was not an expansion of one cell type, but consisted of lymphocyte subclasses resembling those seen in normal healthy individuals. At the time of diagnosis, CML patients had decreased amounts of B cells (7% of lymphocytes vs 20% seen in healthy controls) in the BM, and no maturating and immature forms of B cells were seen. In failure and suboptimal patients (n ¼ 5), the results were similar to CML patients at diagnosis with a decreased amount of B cells (12% of lymphocytes). However, in patients with an optimal response and with BM lymphocytosis, there were normal or increased amounts of B cells in the BM (mean 22%, range, 14-30% of lymphocytes), and immature forms of B-cells were abundantly present. In mature B cells, kappa and lambda light chain expression was polyclonal. CD4/ CD8 T-cell ratio was also normal. The proportion of Tregs in the BM was comparable in different groups (3% of CD4-positive T cells). Decreased amounts of both myeloid dendritic cells (MDC) and plasmacytoid dendritic cells (PDC) were found in the PB and BM of CML patients at diagnosis and also in the PB follow-up samples of poor-responding patients. In optimal responding patients, the amount of MDCs and PDCs was similar to reference values of healthy controls both in the PB and in the BM.
We finally assessed the prognostic value of BM lymphocytosis. Of those patients who had BM lymphocytosis at 3 months, 83% achieved CCR at 12 months and 89% major molecular response (MMR) at 18 months of imatinib therapy (positive predictive value (PPV); Table 2 ). Of those patients who had both lymphocytosis and an MCR (p35% Ph-positive metaphases) in the BM after 3 months of imatinib therapy, all reached MMR at 18 months (PPV 100%, Po0.001). However, if there was neither lymphocytosis nor MCR, none had MMR at 18 months. The PPVs for other more established prognostic variables (for example, diagnostic Sokal or Hasford risk group, PB platelet, basophil or blast counts, age and spleen size) were markedly lower and nonsignificant. Thus, early appearance of a lymphocyte excess in BM during imatinib therapy is a strong and significant predictor of an optimal therapeutic response, especially if combined with cytogenetic response.
In almost all patients with CML, imatinib treatment rapidly normalizes PB counts. However, despite a good initial hematologic response, some fail to show any cytogenetic response. In these patients with treatment failure, there is most likely a BCR-ABL target for imatinib treatment, given the substantial reduction of tumor burden, but for some unknown reason, the majority of the hematopoiesis remains Ph positive. It is similarly unclear why some patients achieve a good molecular response, such as a 3-log reduction of BCR-ABL transcript level, while others do not ('relative primary resistance'). One possible explanation is that in patients with an excellent imatinib treatment response, the immune system participates in the clearance of leukemic cells. Our finding of BM lymphocytosis in patients with an optimal imatinib response would fit well into this hypothesis, as lymphocytes are the key effector cells of Lymphocyte counts in individual patients during imatinib (IM) therapy in various response groups (a: optimal; b: suboptimal; c: failure). The line at 24% shows the upper limit of normal lymphocyte count.
Letters to the Editor immune system. Imatinib treatment can affect tyrosine phosphorylation of intracellular targets in antigen-presenting cells and, therefore, may have an important role in the T-cell activation.
Recent studies suggest that imatinib has both direct and indirect effects on the immune system. Vaccination studies have shown that even prolonged exposure to imatinib does not impair T-cell function 7 and successful vaccination during imatinib leads to expansion of IFN g-producing CD8 þ T cells. However, imatinib can also indirectly affect T-cell activation through restoration of normal hematopoiesis, and induce, for example, IFN-producing plasmacytoid dendritic cells from CD34 þ cells in vitro.
8 Data from our study indicate that successful therapy restores the quantitative defects seen in B-cell and dendritic cell pool at diagnosis. We also observed that the BM lymphocyte proliferation is not an expansion of one lymphocyte subset, but a mixture of various cell types. Further studies concentrating on the functional properties of BM lymphocytes are ongoing and will address the specificity and mechanisms of the proliferative lymphocyte response observed.
BM lymphocytosis was superior in predicting CCR at 12 months or MMR at 12 or 18 months compared to conventional prognostic factors. Appearance of lymphocytosis had a PPV of 89% for MMR at 18 months. If cytogenetic data were combined with the appearance of BM lymphocytosis, even at 3 months of imatinib therapy one could reliably predict the therapeutic response at 18 months: all patients with lymphocytosis and an MCR (p35% Ph-positive cells in BM) at 3 months had an MMR (43 log reduction in BCR-ABL transcript level). Validation of these results in the form of a prospective study with a larger sample size is warranted. However, some patients with optimal response to imatinib therapy had normal BM lymphocyte counts. No significant differences among known risk factors between patients with and without a lymphocytosis response could be found, and further studies are needed to clarify this issue in more detail.
In conclusion, the appearance of BM lymphocytosis is a novel, powerful predictive factor for an optimal molecular response to imatinib. It can readily be determined in all laboratories performing morphological analysis of BM smears, requires no specialized expertise or equipment and is most costeffective. When combined with information on cytogenetic response based on standard G-banding, patients with suboptimal or poor response to imatinib therapy can reliably be identified even after 3 months of therapy (no lymphocytosis and no MCR) and alternative treatments can be considered. We propose that evaluation of BM lymphocyte count could be included in early response evaluation in all patients receiving imatinib mesylate therapy.
